Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.99 USD | -1.25% | -11.53% | -29.85% |
Financials (USD)
Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 5.1B |
---|---|---|---|---|---|
Net income 2024 * | -108M | Net income 2025 * | 171M | EV / Sales 2024 * | 5.81 x |
Net cash position 2024 * | 317M | Net cash position 2025 * | 815M | EV / Sales 2025 * | 3.52 x |
P/E ratio 2024 * |
-47.3
x | P/E ratio 2025 * |
33.8
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | -1.25% | ||
1 week | -11.53% | ||
Current month | -4.98% | ||
1 month | -24.65% | ||
3 months | -38.75% | ||
6 months | -10.64% | ||
Current year | -29.85% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 41.99 | -1.25% | 979,770 |
24-05-09 | 42.52 | +0.52% | 1,060,526 |
24-05-08 | 42.3 | -3.64% | 2,160,470 |
24-05-07 | 43.9 | -10.06% | 4,519,000 |
24-05-06 | 48.81 | +2.84% | 1,849,993 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.85% | 5.1B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- APLS Stock